Abstract 2737
Background
Well-differentiated liposarcomas (WDLPS) can be difficult to distinguish from lipomas. Currently, this distinction is made by testing for MDM2-amplification, which requires a biopsy. The aim of this study was to non-invasively predict the MDM2-amplification status using radiomics, i.e. a combination of quantitative imaging features and machine learning techniques, thereby differentiating between lipomas and WDLPS.
Methods
Patients with a lipoma or WDLPS, a known MDM2-amplification status and a pre-treatment T1-weighted MRI scan who were referred to or diagnosed at the Erasmus MC from 2009-2018 were included. When available, other sequences, e.g. T2-weighted (fat-saturated) MRI, were included in the radiomics analysis. Imaging features describing intensity, shape, orientation and texture were extracted from the tumor segmentations; age, gender, tumor depth and tumor localization were added as semantic features. Classification was performed using an ensemble of various machine learning approaches. Evaluation was performed through 100x random-split cross-validation.
Results
We included 116 patients: 58 patients with lipoma and 58 patients with WDLPS. The dataset originated from 41 MRI-scanners, resulting in large heterogeneity in imaging hardware and acquisition protocols. The best performing radiomics approach to differentiate between WDLPS and lipomas, based on T1-weighted imaging only, resulted in a mean [95% confidence interval] AUC of 0.75 [0.65-0.86], accuracy of 0.68 [0.59-0.77], sensitivity of 0.63 [0.48-0.78] and specificity of 0.73 [0.59-0.87]. A model based on the combination of imaging and semantic featured showed only a minor and non-significant improvement in performance.
Conclusions
There is a significant relationship between a radiomics signature, consisting of a combination of quantitative MRI features, and the MDM2-amplification status. Although further optimization and validation is needed for the transition to clinical practice, radiomics has appeared to be a promising, non-invasive approach for the classification of WDLPS and lipomas.
Clinical trial identification
Editorial acknowledgement
M.Vos and M.P.A. Starmans contributed equally to this study.
Legal entity responsible for the study
The authors.
Funding
Stichting Coolsingel, Netherlands Organisation for Scientific Research, Dutch Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract